Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05219734

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

Sponsor: Invitae Corporation

View on ClinicalTrials.gov

Summary

This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

400

Start Date

2021-11-29

Completion Date

2026-12

Last Updated

2024-03-12

Healthy Volunteers

No

Interventions

DIAGNOSTIC_TEST

Personalized Cancer Monitoring (PCM)

personalized molecular test for solid tumor cancer patients that may detect the presence of circulating tumor DNA (ctDNA) and molecular residual disease (MRD), also known as minimal residual disease

Locations (2)

Columbus Regional Health

Columbus, Indiana, United States

Onslow Radiation

Jacksonville, North Carolina, United States